Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Antigenics commences first phase III trial of its Oncophage cancer vaccine

July 6, 2000

Biomira acquires remaining rights to Theratope from Chiron

July 4, 2000

Cancer immunotherapies based on WT-1 and gata-1 peptide epitopes

July 4, 2000

Cel-Sci receives permission to start phase II cancer trial in Canada

June 30, 2000

StressGen's HspE7 advances to phase III trials in anal dysplasia

June 28, 2000

FDA completes initial review of BLA for Campath

June 28, 2000

Lorus Therapeutics reports strong meta-analysis results for Virulizin, prepares for phase III trials

June 28, 2000

Tumor-associated antigen-derived immunogenic polypeptides useful for cancer immunotherapy

June 23, 2000

Mylotarg now available in U.S. as treatment for relapsed AML

June 22, 2000

Onyvax begins clinical trials for colorectal cancer vaccines

June 15, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
CINP 2026: organoids reveal autism and addiction mechanisms
BioWorld Science
At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Reunion Neuroscience reports new 5-HT2A partial agonists and/or 5-HT2B antagonists
BioWorld Science
Reunion Neuroscience Inc. has identified new 5-HT2A receptor partial agonists and/or 5-HT2B receptor antagonists potentially useful for the treatment of...
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...